Formosa Laboratories, Inc.

Taiwan Stock Exchange 4746.TW

Formosa Laboratories, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 1.85

Formosa Laboratories, Inc. Price to Sales Ratio (P/S) is 1.85 on January 14, 2025, a -35.87% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Formosa Laboratories, Inc. 52-week high Price to Sales Ratio (P/S) is 3.23 on January 26, 2024, which is 74.66% above the current Price to Sales Ratio (P/S).
Formosa Laboratories, Inc. 52-week low Price to Sales Ratio (P/S) is 1.78 on December 27, 2024, which is -3.90% below the current Price to Sales Ratio (P/S).
Formosa Laboratories, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 2.55.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Taiwan Stock Exchange: 4746.TW

Formosa Laboratories, Inc.

CEO	Dr. Chen-Yu Cheng Ph.D.
IPO Date	Feb. 28, 2011
Location	Taiwan
Headquarters	36 Hoping Street
Employees	867
Sector	Health Care
Industries Pharmaceuticals

Description

Formosa Laboratories, Inc. produces and sells active pharmaceutical ingredients (APIs) worldwide. The company offers APIs in the areas of anticancer, anti-inflammatory and analgesic agents, MRI enhancing agents, cholesterol and phosphate binders, CNS agents, immunomodulators, respiratory agents, steroids, vitamin D derivatives, and antibiotics. It also provides contract development and manufacturing services; solutions for manufacturing antibody-drug conjugates; and injectable manufacturing services. The company was founded in 1995 and is based in Taoyuan City, Taiwan.

Key trends

Past 5 years